Navigation Links
Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
Date:7/4/2008

BASINGSTOKE, England and PHILADELPHIA, July 4 /PRNewswire-FirstCall/ -- Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce second quarter 2008 earnings on Thursday 31 July 2008

Results press release will be issued at: 12:00 BST / 07:00 EDT

Investor meeting and conference call time: 14:30 BST / 09:30 EDT

Investor & Analyst meeting and conference call:

Angus Russell, Chief Executive Officer, Graham Hetherington, Chief Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie Grégoire, President, Human Genetic Therapies will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT.

The meeting will take place at Holborn Bars, 138-142 Holborn, London EC1 2NQ.

Please email claire.rowell@fd.com to register to attend this meeting in London.
The details of the conference call are as follows:

UK and International dial in +44-(0)-203-023-4496

US dial in: +1-866-966-5335

Password/Conf ID: Shire

Live Webcast:

The call will also be available live over the Internet via audio webcast, accessible through http://www.shire.com in the investors section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:

UK and International dial in +44-(0)-208-196-1998

US dial in +1-866-583-1035

Pin code 3008632

Webcast replay: http://www.shire.com, in the investors

section

Notes to Editors

SHIRE LIMITED Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact:

Investor Relations

Souheil Salah (Rest of the World) +44-1256-894-160

Emily Berish (North America) +1-484-595-8546


'/>"/>
SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). ... two years to develop a suite of BioGel™ biopolymer materials for hygiene applications, ...
(Date:3/28/2017)... 2017  The National Pharmaceutical Council (NPC) today announced ... research organization as its newest member. David Cox ... North America ), will serve as his ... "We,re pleased to have Ipsen and Dr. Cox join ... . "We welcome their insights in helping us identify ...
(Date:3/28/2017)... ... March 28, 2017 , ... Currently ... over time. A recent study published in STEM CELLS suggests that human neural ... (SVZ) stem cells to produce more neural cells. , Strategies involving transplantation ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search ... with Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a ... is a leader in a wide range of services related to laboratory testing ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... 2017 Vigilant Solutions , a vehicle ... agencies, announced today the appointment of retired FBI special ... safety business development. Mr. Sheridan brings more ... a focus on the aviation transportation sector, to his ... Mr. Sheridan served as the Aviation Liaison Agent Coordinator ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
Breaking Biology News(10 mins):